# Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration

> **NCT01628354** · PHASE4 · COMPLETED · sponsor: **University of Melbourne** · enrollment: 49 (actual)

## Conditions studied

- Choroidal Neovascularization
- Retinal Pigment Epithelial Detachment

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01628354
- **Lead sponsor:** University of Melbourne
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2012-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01628354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01628354, "Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01628354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*